Chapter 69: Mood Disorders

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine you are in exam room three.

You've got a 19 -year -old patient sitting on the paper line table and they just look, well, completely exhausted.

Right.

Yeah.

Their chief complaint on the chart just says fatigue.

But as you start taking their history, it becomes pretty clear that we are dealing with a mood disorder.

And usually when we talk about a medical diagnosis, there's this expectation of precision.

Like an engineering problem.

Exactly.

Like you break your arm, the x -ray shows that jagged white line, and you just point to it and say, there it is.

It's totally binary, broken or not broken.

It is clean and honestly, it's comforting.

We like things to be visible and perfectly categorized, especially when we're trying to fix them.

Yeah.

But when you step into the world of psychiatric illness,

that x -ray machine is entirely useless.

I mean, you really have to rely on clinical reasoning, patient history, and this understanding of completely invisible biological mechanisms.

Right.

And if you are an advanced practice nursing student or a practitioner gearing up for the diagnostic murkiness every single day.

Every day.

For sure.

So welcome to another depth dive.

Today our mission is to navigate chapter 69 on mood disorders from the primary care text.

But more importantly, we are giving you the tools to handle these clinical puzzles in primary care because frankly, you are the absolute first line of defense here and the stakes are incredibly high.

Think of this as like a one -on -one tutoring session.

Our goal today is to help you synthesize the foundational science of these disorders with the actual clinical reasoning you are going to need when that patient is sitting across from you.

So you don't just freeze up.

Exactly.

We want you feeling confident, not overwhelmed as we move from pathophysiology all the way to crisis management.

Okay.

Let's unpack this.

Let's start with just the sheer scope of major depressive disorder or MDD.

You might think specialists handle most of this, but primary care is where the vast majority of mental health treatment actually happens.

Oh, absolutely.

The bulk of it.

And the numbers are just staggering.

Globally, more than 254 million people suffer from depression.

In the U .S.

alone, 8 .4 % of adults will experience MDD in their lifetime.

What's really fascinating here is how those demographics break down.

It doesn't hit everyone equally.

Right.

The textbook points that out.

Yeah.

We see significantly higher rates in females, around 10 .5%.

And when we look at that hypothetical 19 -year -old in exam room 3, the prevalence in 18 - to 25 -year -olds is a massive 17%.

You are going to see this constantly in practice.

Wow.

17%.

Here's where it gets really interesting for me, though.

Looking at the pathophysiology, we used to just tell patients, oh, you know, depression is a chemical imbalance.

You just need more serotonin.

The neat little package.

Right.

It was easy to explain, but the science has moved way past that now.

The chapter emphasizes that we now use a network and circuit model.

Yeah, that chemical imbalance theory is outdated because it's just far too simplistic.

We're now looking at how different areas of the limbic system interact, and crucially, how they structurally change.

Structurally?

Like physical changes in the brain?

Yes, physical changes.

For instance, in a depressed patient, the amygdala, which is the brain's fear and mood dysregulation center,

becomes chronically hyperactive.

It is constantly sounding the alarm.

Geez.

That sounds exhausting.

It is.

And meanwhile, the hippocampus, which is crucial for emotional regulation and long -term memory, actually shrinks.

And it keeps shrinking with recurrent depressive episodes.

So it's not just a software glitch.

For years, we basically told patients their chemicals were just mixed up, like bad code.

But really, the hardware itself structures, like the hippocampus, is actively taking on physical damage under the strain of recurrent episodes.

Exactly.

The hardware is degrading.

Why does that shrinkage happen, though?

It really comes down to cellular toxicity and the endocrine overlap.

The text mentions the hypersecretion of cortisol in depressed patients.

Chronic stress just floods the brain with glucocorticoids, like cortisol.

And too much of that is toxic.

Highly toxic.

Over time, high levels of cortisol become toxic to the neurons in the hippocampus, basically halting neurogenesis, the birth of new brain cells, and causing existing dendrites to wither.

Wow.

That perfectly explains the cognitive fog and memory issues depressed patients are always complaining about.

It's a structural damage.

And while neurotransmitters are still a huge piece of the puzzle, the text points out it is highly nuanced.

We are looking at a specific polymorphism in the 5 -HTT gene involving serotonin that links directly to stress, vulnerability, and suicide risk.

Yes.

The genetics play a huge role.

Plus, we have a norepinephrine, which impacts energy and blood pressure, and dopamine.

And when dopamine drops, you see that profound apathy and a total loss of the brain's reward mechanisms.

And if we connect this to the bigger picture, this is why we don't just tell patients to cheer up.

Understanding this pathophysiology proves to you, the provider, that MDD is a systemic biological illness.

Isn't it just sadness?

Not at all.

It is altering brain volume, genetic expression, and endocrine function.

And speaking of endocrine function,

5 -10 % of depressed patients actually have a coexisting thyroid disorder.

Which perfectly brings us to the diagnostic puzzle.

So you have that exhausted young adult in your exam room.

The U .S.

Preventive Services Task Force recommends starting with the PHQ -2, right?

Yep.

The PHQ -2.

Which is just a quick two -question preliminary screen asking about mood and interest.

If that is positive, you immediately pivot to the PHQ -9.

The PHQ -9 is really your clinical workhorse here.

It quantifies the severity of the symptoms.

But to actually meet the DSM -5 -TR diagnostic criteria for MDD, your patient needs to report five or more specific symptoms present nearly every day during a two -week period.

And there's a big caveat there, right?

A huge caveat.

At least one of those symptoms absolutely must be either depressed mood or anhedonia.

Anhedonia being that dopamine -driven loss of pleasure and things they used to love.

Exactly.

The textbook also features some incredible qualitative research looking at postpartum depression, just to give us a real sense of what this feels like for the patient.

Oh, Evidence -Based Practice 69 .1.

Nice.

That one.

The researchers described the experience as teetering on the edge.

The patients felt like they were caught in this terrifying limbo between sane and insane, experiencing a complete loss of self.

That's a haunting metaphor.

It really is.

It really grounds those dry DSM criteria in human reality.

It does.

And it reminds us to listen closely to this subjective experience.

But as an advanced practice nurse, you also have to be an objective detective.

You must actively rule out differential diagnoses and medical mimics before just handing out a psychiatric label.

Right.

Because of the thyroid connection we mentioned, checking a TSH level is pretty much mandatory.

Vandatory.

And we have to look for neurological disorders too, like Parkinson's disease can present with severe depressive symptoms long before the classic tremors appear.

Wait, really?

Before the tremors?

Long before.

Even right -sided temporal lobe epilepsy can mimic a depressive disorder because of how emotion is lateralized in the brain.

That's wild.

And I guess we have to do a ruthless medication reconciliation too.

Always.

Beta blockers for hypertension, systemic steroids, sedatives, they can all chemically induce depressive symptoms.

So once you have confidently ruled out the medical mimics and confirmed its MDD, we shift to evidence -based management.

The clinical target here is remission.

We define remission as a PHQ -9 score under 5.

Which means a virtual absence of symptoms, not just a partial reduction.

Okay, let me push back on that for a second.

Let's say I have a patient who comes in severely depressed, completely unable to get out of bed, and after a few weeks on an SSRI they say they feel like 50 % better and are back at work.

Okay.

Isn't that a massive clinical win?

Why push the medication further and risk more side effects if they are basically functioning again?

I mean, it absolutely feels like a win.

And you should definitely validate that patient's progress.

But accepting incomplete relief is dangerous long term.

Why is that?

Because when symptoms only partially resolve,

those neural circuits we talked about, the hyperactive amygdala, the damaged tip of campus, they remain vulnerable.

Leaving a patient with residual symptoms significantly increases their risk for a rapid and often much more severe relapse.

Ah, I see.

You have a four to six week optimization window.

If you aren't reaching remission, you need to maximize the dosage of their current drug before switching classes.

That makes total sense when you think about it structurally.

You wouldn't leave a broken bone partially set.

Exactly.

Great analogy.

So looking at the pharmacology tables in the text, we have our SSRIs, SNRIs, and NDRIs like bupropium.

The golden rule across the board seems to be start low, go slow.

Especially in older adults who metabolize drugs differently or in pediatric patients.

Start low, go slow.

Always.

And if you do need to switch medications, you have to cross taper carefully to avoid severe withdrawal syndromes.

Safety is absolutely paramount here.

You must monitor for the black box warnings regarding increased suicidal behavior in children, adolescents, and young adults during the initial weeks of antidepressant therapy.

That's a huge red flag to watch for.

And you also have to aggressively screen for over -the -counter supplements.

If a patient combines an SSRI with something like St.

John's wort, you are risking serotonin syndrome.

Which is potentially fatal, right?

That autonomic and neuromuscular hyperreactivity.

Yes, it is a medical emergency.

Okay, let's follow a clinical scenario that highlights probably the most dangerous trap in this entire process.

Okay, let's hear it.

You've done everything right.

You screened the patient, diagnosed depression, and prescribed an SSRI.

Two weeks later, the patient's family calls you in a panic.

The patient hasn't slept in four days, they just bought three cars they can't afford, and they are talking a mile a minute.

What did we miss?

You missed the bipolar screen.

The bipolar screen.

Before you ever prescribe an antidepressant to a patient with suspected unipolar depression,

the guidelines mandate that you screen them for bipolar disorder.

Every single time.

Every time.

If a patient actually has undiagnosed bipolar disorder,

giving them an antidepressant monotherapy, meaning an antidepressant without a mood stabilizer on board, can literally thrust them into a full -blown manic episode.

I want to make sure I understand the actual mechanism there.

Is it because the SSRI is flooding the synaptic cleft with serotonin acting like fuel, but the bipolar brain already has unregulated receptor sensitivity, like it lacks the braking system to down -regulate?

That is a phenomenal way to conceptualize it, yes.

You aren't just giving them energy, you are overstimulating a neural network that is already primed for hyper -excitability, and it simply cannot hit the brakes.

It's like pouring nitrous oxide into a race car with no brakes.

Exactly.

It's incredibly dangerous.

And the statistics on missed bipolar diagnoses are honestly heartbreaking.

On average, there is a 5 to 10 -year delay in accurate diagnosis.

Which is a tragic amount of time to suffer.

It is.

These patients typically bounce around and see an average of four different providers before someone finally spots the mania.

And the stakes couldn't be higher, because bipolar disorder carries a suicide rate 10 to 30 times higher than the general population.

To understand why it's so hard to diagnose and so volatile,

we really have to look at the genetics and the epigenetics.

There isn't one single bipolar gene.

However,

the CAC ANA1C gene, which codes for calcium channels, is heavily implicated.

When calcium channels dysregulate, it leads to massive cellular excitability.

And the heritability is pretty striking, too.

Oh, very.

Concordance rates in monozygotic identical twins can be up to 70%.

But DNA isn't destiny, right?

Environment plays a massive role through epigenetics.

The textbook points out that childhood maltreatment is four times higher in bipolar patients compared to their peers.

Four times higher.

That's a huge correlation.

And that trauma actually changes gene expression through a process called methylation.

Can you explain how that actually works for us?

Sure.

Think of DNA as sheet music, and epigenetics as the conductor.

Methylation involves chemical tags, methyl groups physically attaching to the DNA.

They act like volume knobs.

So they turn genes up or down.

Severe childhood trauma literally adds these tags to silence or turn down the genes responsible for stress regulation.

This altered reading of the DNA leads to an earlier onset of bipolar disease and much more severe, rapid -cycling episodes later in life.

So you really have to take a comprehensive, trauma -informed history.

Absolutely essential.

And when assessing for bipolar, you are looking to differentiate between three main categories.

First, bipolar 1.

This requires at least one manic episode lasting at least one week, marked by severe impairment,

hospitalization, or psychosis.

And interestingly, a major depressive episode isn't strictly required for a bipolar eye diagnosis, though it almost always happens.

Okay, then there is bipolar 2.

This requires a current or past hypomanic episode, which is less severe, lasting at least four days without psychosis or hospitalization plus a major depressive episode.

Right, the hypomania is the key there.

Finally, you have cyclophamic disorder, which involves two full years of subsyndromal hypomanic and depressive symptoms that never quite meet the full criteria, but they cause chronic instability.

To spot that mania or hypomania in the clinic, the text uses the DMG FAST mnemonic.

Let's walk through that.

Distractability.

Insomnia, and this is specifically a decreased need for sleep, not just tossing and turning.

Correct.

They feel rested after two hours.

Wow.

Then grandiosity, flight of ideas, increased goal -directed activities, pressured speech, and thoughtlessness, meaning impulsive, high -risk behaviors like gambling or hypersexuality.

Spot on.

In primary care, your go -to screening tool to catch this is the MDQ, the mood disorder questionnaire.

If that MDQ comes back positive, your management path pivots completely.

And because you cannot use antidepressants alone.

Exactly.

You must establish mood stabilization first.

When we look at that pharmacologic stabilization in the text, lithium remains the absolute gold standard.

And what makes lithium so unique is that it is the only mood stabilizer proven to actively decrease suicidal behavior.

It is incredible for that, but the monitoring is intense.

Yeah, the textbook makes that very clear.

It has a notoriously narrow therapeutic window because of how it is cleared by the kidneys.

Serum levels must be drawn exactly 12 hours post -dose.

That's very specific.

It has to be.

Toxicity, which can cause severe neurological and renal damage, occurs at levels over 2 .0 miQL.

You also have to screen for pregnancy.

And lithium exposure in the first trimester carries a high risk of Epstein's anomaly, which is a severe cardiac defect.

We also use valproic acid, which is first line for rapid cycling bipolar.

But this has massive red flags for females of childbearing age.

Massive.

It alters endocrine function, often causing polycystic ovary syndrome, or PCOS.

And it carries a very high risk of neural tube defects in a fetus.

So you really want to avoid it in that demographic.

Definitely.

For maintenance therapy, there is Lammatrigine, but you have to watch closely for the Stevens -Johnson syndrome rash, which is a life -threatening immune -mediated skin reaction.

That's the one where the skin basically blisters and peels, right?

Yes.

It's a dermatological emergency.

And increasingly, we rely on second -generation antipsychotics like Quichipine or Loracidone to manage bipolar depression.

This raises an important question about the reality of long -term care.

You finally get a patient stabilized on these heavy -duty medications.

How do you keep them compliant when they start missing the euphoric productivity and creativity of their hypomanic phases?

I mean, that has to be the biggest hurdle in clinical practice.

Right.

When they're hypomanic, they feel invincible.

They don't want to trade that high for a medication that might make them feel flattened, sluggish, or emotionally blunted.

It is a profound clinical challenge.

This is where psychoeducation and aggressive sleep hygiene become vital.

Sleep hygiene?

Really?

Yes.

You have to work collaboratively to help them understand that irregular sleep isn't just a symptom.

It is a primary trigger for a manic relapse.

Wow.

And the data in the text is clear.

81 % of partially -adherent bipolar patients end up requiring hospitalization compared to just 9 % of fully -adherent patients.

It is a staggering difference.

81%.

That is wild.

Which brings us to a devastating reality that kind of hovers over everything we have discussed today.

Over 45 ,000 Americans die by suicide annually.

It's a tragedy.

And as a primary care provider, you are sitting at ground zero.

Primary care writes 80 % of all antidepressant prescriptions.

Let that sink in.

80%.

In the months before a patient dies by suicide, they are far more likely to have seen you their primary care provider than a mental health specialist.

You are the absolute front line.

Assessing acute suicide risk is the single most critical skill you will develop.

The textbook uses the SAB persona's mnemonic to systematically evaluate risk factors, right?

Yes.

Sex, age, depression, previous attempt, ethanol abuse, rational thinking loss, social support loss,

organized plan, no spouse, availability of lethal means, and sickness.

Looking at that list, it really feels like previous attempt carries the most weight.

If a patient has crossed that psychological barrier once, the threshold to try again is permanently lowered.

Is that the biggest red flag?

You hit the nail on the head.

The absolute best statistical predictor of future suicide risk is a history of a previous attempt.

So imagine stepping into clinicals as a student.

I have to admit, there is this lingering,

terrifying anxiety about asking a patient directly about suicide.

It's a very common fear.

There is this deeply ingrained thought.

Won't asking them, are you thinking about killing yourself,

plant the idea in their head if it wasn't there already.

I am so glad you brought that up because we need to firmly and permanently dispel that myth right now.

Okay, good.

Asking directly does not trigger suicide.

It does not put the idea in their head.

Asking directly lowers patient anxiety and it saves lives.

Really?

It lowers anxiety.

Yes.

It often provides a profound sense of relief to the patient that someone finally sees how much pain they're in and is actually willing to talk about it without flinching.

To structure that conversation, the textbook points us to the SAFE -ET five -step evaluation and the CSSRS, the Columbia Suicide Severity Rating Scale.

You have to evaluate SAL, the specificity of their plan, the availability of the means and the lethality of the chosen method.

If a patient is at an acute, high risk, meaning they have intent and access to highly lethal means, you must initiate involuntary or voluntary hospitalization.

You don't just send them home.

Do not leave them alone.

And we need to be very clear about clinical folklore.

No suicide contracts where a patient signs a piece of paper promising not to hurt themselves are clinically useless.

Completely useless.

Completely.

They do not prevent suicide and they offer zero protection from malpractice litigation.

Okay, but what if the patient is at a lower risk and does not require immediate hospitalization?

Then your goal shifts to safety planning.

You use the Primary Care Mental Health Crisis Safety Plan outlined in table 69 .4.

Which isn't a promise not to die, it is a functional strategy to live.

Beautifully said.

You work with the patient to build scaffolding.

You restrict access to lethal means by having a family member secure firearms or remove pill stashes.

You are essentially putting physical friction between the suicidal impulse and the action.

You also help them list internal coping strategies and give them direct contact information for

247 crisis hotlines.

You are engineering a safe environment so that when the cognitive distortion of a mood disorder hits its peak, the pathway to self -harm is blocked.

We have covered a massive amount of ground today.

From understanding how toxic cortisol shrinks the hippocampus and MDD to the absolute necessity of ruling out bipolar mania before prescribing an SSRI.

And of course, the life -saving reality of asking your patients directly about their suicide plans.

Right.

And as we wrap up, I want to leave you with one final striking realization from the text.

When we look at risk factors for suicide,

serious physical illness in any organ category is an independent risk factor.

Any organ category.

Any of them.

This is particularly true in older adults who have a shocking four to one attempt to completion ratio.

They do not usually give warnings and they use highly lethal means.

So when you are treating an older patient for congestive heart failure or severe osteoarthritis or COPD,

you aren't just managing their physical body.

Not at all.

Because of the pain and the loss of independence, you are actively managing their suicide risk.

Which brings us back to exam room three and the broken bone x -ray we started with.

Human beings aren't binary.

The mind and the body are not separate ecosystems.

How might your primary care practice transform if you truly completely stopped separating the two?

That is the challenge you are taking on every time you put on the stethoscope.

On behalf of the Deep Dive and the Last Minute Electricity team, we want to thank you so much for joining us to Master Chapter 69.

We wish you the absolute best of luck on your exams and, more importantly, in your future clinical practice.

You've got this.